Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2625567 | 0.78 | EPHX1 (0.47) | EPHX1ALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL23437494 | 0.77 | EPHX1 (0.47) | EPHX1ALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL12449180 | 0.76 | EPHX1 (0.46) | EPHX1ALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL20686302 | 0.74 | EPHX1 (0.41) | EPHX1ALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL24568621 | 0.72 | MLYCD (0.35) | EPHX1ALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL19068846 | 0.72 | EPHX1 (0.46) | EPHX1ALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL5019737 | 0.71 | POLB (0.48) | EPHX1ALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL2625566 | 0.70 | EPHX1 (0.48) | EPHX1ALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL20017286 | 0.69 | EPHX1 (0.52) | EPHX1ALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL1233423 | 0.67 | TSHR (0.39) | EPHX1ALDH1A1MEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220160705-A1 | METHODS FOR CONTROLLING PROSTAGLANDIN-MEDIATED BIOLOGICAL PROCESSES | CORNELL UNIVERSITY | 2022-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220160705-A1 | METHODS FOR CONTROLLING PROSTAGLANDIN-MEDIATED BIOLOGICAL PROCESSES | PTGES, PTGS1, PTGES2 | EPHX1 63/4885ALDH1A1 901/4885MEN1 4785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.